



## Centre and Fields Digest



Dear Colleagues,

After a break over April for the Cochrane Governance Meetings (the new name for the Mid-Year meetings), welcome to the 19th edition of the Centre & Fields Digest. Grateful thanks to Claudia Burdet and all the staff at Cochrane Switzerland for hosting us in the beautiful city of Geneva. Thanks also to all those who attended the meetings from around the world. You will be receiving the minutes from the various meetings you attended in the coming weeks.

A reminder that the Digest provides information particularly relevant to Cochrane Centres and Fields, including consumers, and will include a round-up of pertinent information also published in the Community newsletter and on the Cochrane websites. It is the sister publication to the [Review and Methods Digest](#) published by the Cochrane Editorial Unit, which is sent to CRGs and Methods Groups.

***Please note that Group staff and contributors are not automatically added to the email lists receiving this Digest and other official Cochrane emails, even if they have been added to the Archie database. Staff at Centres and Fields should ensure new colleagues are signed-up to receive emails through the Cochrane email lists by contacting [admin@cochrane.org](mailto:admin@cochrane.org).***

### **ITEMS FOR YOUR ACTION:**

#### **1) Call for Nominations: Cochrane Governing Board members - deadline 20 June 2017**

**Do you want to help shape Cochrane's strategic direction and build your leadership profile? We now invite you to apply to help lead the organization to 2020 and beyond.**

Due to the expiry of current terms of existing Governing Board members, we are seeking to elect and appoint:

- Two internal members
- Three external members
- One Co-Chair

You must have strong leadership skills, vision, and expertise, and be able to play a pivotal role in Cochrane's future success. You will bring high levels of personal integrity to the role and a commitment to working in a multi-cultural, geographically diverse organization. You must be able to challenge and debate constructively, whilst exemplifying mutual trust and respect for other Board members. Candidates who have not served at a board/director level before are welcome to apply.

For more information and details of how to nominate, please visit the [Cochrane Community Board Elections](#) page.

#### **2) Cochrane's 2012 Annual Review published**

[Cochrane's 2012 Annual Review](#) has been published today in an exciting new interactive format with videos and multiple links that make it an ideal product to share with your external funders, stakeholders and supporters.

Find out more about Cochrane's key achievements during 2016, and the strides being made on our major [Strategy to 2020](#) initiatives. Hear from our Community, get the latest financial standing, and our geographical reach. Read more about the improvements to our products, ways of working, outreach and, most importantly, how Cochrane Reviews are making a difference on health decision making by users of our evidence across the world.

All Centres and Fields are encouraged to distribute and use the Annual Review widely. If you want to use parts of the Annual Review for your own presentations or other reports or promotional material, please contact Jo Anthony at [janthony@cochrane.org](mailto:janthony@cochrane.org).

### **3) Would you like to host a future Cochrane Colloquium or Governance Meeting? Deadline for submissions 28 July 2017**

We are looking for Cochrane Groups to host the 2020 and 2021 Cochrane Colloquia; and the 2019, 2020 and 2021 Cochrane Governance Meetings. For more information, please see the [Cochrane Community website](#).

### **4) Sponsored Group registration for the Global Evidence Summit 2017 – deadline 1 June 2017**

The Governing Board is delighted to announce that sponsored registration for one person from each Cochrane Group to attend Cochrane Colloquia has been extended to **Associate Centres** and **Satellites of Cochrane Review Groups**. This also applies to the [Global Evidence Summit](#) in Cape Town, from 13-16 September 2017, which this year replaces the normal Cochrane Colloquium. Sponsored Group registrants will be required to pay for their own travel, accommodation, optional or additional social events tickets.

- For more information, please see the [Cochrane Community website](#).
- [Early bird registration](#): Register before the 30 June 2017 to get over 11% off the standard ticket price for the GES.

### **5) Recognizing and celebrating contributors who deliver outstanding work for Cochrane – call for nominations for Cochrane prizes and awards by 30 June 2017**

Every year Cochrane awards members of its community a range of prizes that highlight high-quality methodological research through to supporting health decision-making in developing countries, and contributors who have made a significant contribution to the enhancement of female participation within our organization. The prizes and awards that are presented at the annual Colloquia will this year be awarded at the [Global Evidence Summit](#) in Cape Town, South Africa on 14 September.

Submissions to the Kenneth Warren, Chris Silagy, and Bill Silverman Prizes as well as the Anne Anderson Award are now open. You have until the 30 June 2017 to make your nominations. For more information, please see the [Cochrane Community website](#).

### **6) Invitation to join the MedLit Blitz – 9-12 May 2017**

[Cochrane Crowd](#) has run several successful citation screening challenges and they're upping the ante by running a bigger event, the MedLit Blitz, with Mark2Cure. And it just so happens to coincide with the anniversary of both platforms *and* with [Citizen Science Day 2017](#). Get ready to celebrate!

For more information, please see the [Cochrane Community website](#).

**ITEMS FOR YOUR INFORMATION:**

### **7) Decisions from the Cochrane Governing Board meeting, April 2017**

Please see the [Cochrane Community site](#) for the main decisions made by the Cochrane Governing Board (previously known as Steering Group) at its meeting in Geneva, Switzerland, 5-7 April. If you have any questions about these decisions, please contact a [member of the Board](#).

The next Governing Board face-to-face meeting is 10-12 September 2017 in Cape Town, South Africa.

### **8) Cochrane Taiwan announces appointment of new Director**

We are pleased to announce that Cochrane Taiwan has appointed Chiehfeng (Cliff) Chen as its new Director, effective February 2017. Grateful thanks to founding Director, Ken Kuo, for his leadership since 2003.

To read the full article on this, please see [Cochrane.org](#).

### **9) Launch of Cochrane Global Mental Health**

We are pleased to announce the development of Cochrane Global Mental Health: a partnership that brings together the five Cochrane Review Groups that cover mental health conditions and the WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Section of Psychiatry and Clinical Psychology.

To read the full article on this, please see the [Cochrane Community website](#).

### **10) Cochrane Croatia and Cochrane Poland collaborate**

The University of Split School of Medicine, in Split, Croatia, had the pleasure of hosting Cochrane Poland's director, Malgorzata Bala, 6-9 March 2017, during her visit to Cochrane Croatia. Given Croatia and Poland's similar health and education systems, cultural background and Cochrane Group setting (both are based at a medical school), it was felt that a visit would be mutually beneficial and contribute towards future progress and collaboration. To read the full article on this, please see the [Cochrane Community website](#).

### **11) Cochrane Priority Reviews List: Update May 2017**

The May 2017 revision of the Cochrane Priority Reviews List includes new titles from the Cochrane Airways, Back and Neck, Heart, Movement Disorders, Schizophrenia and Tobacco Addictions Groups.

For more information, please see the [Cochrane Community website](#).

### **12) Reminder - free use of Covidence for Cochrane Groups that are directly conducting non-Cochrane systematic reviews**

Covidence is the primary screening and data extraction tool for Cochrane authors, streamlining the production of standard intervention reviews. Covidence's support of key steps in the Cochrane Review process, such as citation screening and Risk of Bias assessment, and improved links with RevMan, make the review writing process more efficient.

Covidence access is also provided free to all Cochrane Groups for work that is undertaken by them on non-Cochrane systematic reviews. To access Covidence in this way, please email Julian Elliott from the Central Executive Team: [julian.elliott@monash.edu](mailto:julian.elliott@monash.edu).

**CORRECTION:** Please note that in previous editions of this announcement, it was incorrectly stated that the Cochrane Editorial Unit (CEU) would be routinely monitoring access to Covidence for work undertaken on non-Cochrane systematic reviews. The Central Executive Team intends to monitor use, but has not yet allocated the task.

### **13) Latest Cochrane Community news posts and blogs**

- [Upcoming events](#)
- [Survey round-up: May 2017](#) - Plain Language Summaries project; and Testing the AGREE-REX Tool
- [2016 Dashboard now available](#)
- [Call for applications: Cochrane Review Support Programme](#)

**Community blogs:**

- [Cochrane goes to the March for Science](#)
- [Cochrane and WHO meet to discuss how to improve their long-standing partnership](#)
- [TaskExchange Profile: Elizabeth Clearfield, regular task poster](#)

The Centre & Fields Digest is created by the Chief Executive Officer's Office. We intend to make it available approximately every two weeks and to bring together various items of content that we think will be of interest, to maximise communication and minimise inbox overload. If you wish to submit content please contact [Lucie Binder](#), Senior Advisor to the CEO. We hope that you will find the Digest interesting and informative, and also that it will provide you with opportunities for communicating your views and suggestions.

Best wishes,

**Mark G. Wilson**

Chief Executive Officer



E [mwilson@cochrane.org](mailto:mwilson@cochrane.org) T +44 (0)207 183 7503 S [mark.g.wilson](mailto:mark.g.wilson@cochrane.org)  
Cochrane, St Albans House, 57-59 Haymarket, London SW1Y 4QX, UK  
[www.cochrane.org](http://www.cochrane.org)

**Trusted evidence. Informed decisions. Better health.**